Acrylonitrile is a potent CNS tumorigen in rats leading to concern that it may be a tumorigen in humans. There have been 12 epidemiology studies of 37,352 workers exposed to acrylonitrile which evaluate CNS cancers. We summarize and evaluate these epidemiology studies for CNS cancers using the methods of meta-analysis. Our analyses indicate that workers with acrylonitrile exposure have null ndings for CNS cancer (relative risk = 1.1, 95% condence interval 0.8-1.5), which are in stark contrast to the projected risk to humans using the rat ndings (relative risk = 3.5, 95% con dence interval 3.0-4.0). We discuss several explanations for the inconsistency between animal and human ndings, including the possibility that the acrylonitrile-induced rat CNS tumors may not be relevant to humans. Given the rarity of CNS tumors in humans and a lack of understanding of the causal mechanisms of these tumors in rats, however, a more de nitive conclusion will have to await additional experimental and observational data. Nevertheless, the epidemiology evidence indicates that acrylonitrile is not a potent CNS tumorigen. NeuroOncology 1, 221-230, 1999 (Posted to Neuro-Oncology [serial online], Doc. 99-10, June 9, 1999 A crylonitrile (CAS No. 107-13-11) is an intermediary chemical used in the manufacture of acrylic bers, resins, plastics, rubbers, and other chemicals such as acrylamide. Acrylonitrile has been in commercial production since 1940. Currently, 125,000 workers are potentially exposed to acrylonitrile in the United States (OSHA, 1978). In the late 1970s, chronic bioassays of rats exposed to acrylonitrile through drinking water or inhalation produced cancers at several sites including the CNS (Strother et al., 1988) . These ndings in experimental animals and some small epidemiology studies (Keisselbach et al. , 1980; O'Berg et al., 1980a; Thiess et al., 1980) led to speculation that acrylonitrile exposure by humans may increase their risk of CNS cancers (Thomas, 1994; Thomas and Waxweiler, 1986 ). Reviews of the epidemiology studies have focused on increased risks of lung and prostate cancer among acrylonitrile workers, but cancers of CNS have not been examined in detail (ATSDR, 1990; Blair and Kazerouni, 1997; Collins and Acquavella, 1998; Doll, 1991; EPA, 1990; Guirguis et al., 1984; IARC, 1987; Koerselman and van der Graaf, 1984; Rothman, 1994; Strother et al., 1988) . Recently, three large epidemiology studies have examined cancer levels, including CNS cancers among workers exposed to acrylonitrile Swaen et al., 1998; Wood et al., 1998) . We will determine if the CNS cancer rates among acrylonitrile workers are consistent with the increased risk of CNS cancer observed in test animals.
A crylonitrile ) is an intermediary chemical used in the manufacture of acrylic bers, resins, plastics, rubbers, and other chemicals such as acrylamide. Acrylonitrile has been in commercial production since 1940. Currently, 125,000 workers are potentially exposed to acrylonitrile in the United States (OSHA, 1978) . In the late 1970s, chronic bioassays of rats exposed to acrylonitrile through drinking water or inhalation produced cancers at several sites including the CNS (Strother et al., 1988) . These ndings in experimental animals and some small epidemiology studies (Keisselbach et al. , 1980; O'Berg et al., 1980a; Thiess et al., 1980) led to speculation that acrylonitrile exposure by humans may increase their risk of CNS cancers (Thomas, 1994; Thomas and Waxweiler, 1986 ). Reviews of the epidemiology studies have focused on increased risks of lung and prostate cancer among acrylonitrile workers, but cancers of CNS have not been examined in detail (ATSDR, 1990; Blair and Kazerouni, 1997; Collins and Acquavella, 1998; Doll, 1991; EPA, 1990; Guirguis et al., 1984; IARC, 1987; Koerselman and van der Graaf, 1984; Rothman, 1994; Strother et al., 1988) . Recently, three large epidemiology studies have examined cancer levels, including CNS cancers among workers exposed to acrylonitrile Swaen et al., 1998; Wood et al., 1998) . We will determine if the CNS cancer rates among acrylonitrile workers are consistent with the increased risk of CNS cancer observed in test animals.
Toxicity Studies
Acrylonitrile is a potent CNS tumorigen in rats. At least seven long-term studies have been conducted by various routes of exposure, and CNS tumors have been observed consistently in rats exposed for one year or longer (Strother et al., 1988) . CNS tumor excesses have occurred at exposure to 20 ppm 2 in an inhalation study. Chronic bioassays on acrylonitrile have not been reported in other experimental species.
The rat chronic bioassay ndings have led to concern about increased cancer risk of workers exposed to acrylonitrile. This concern is ampli ed by the fact that exposure to acrylonitrile has been shown to produce CNS tumors in rats at concentrations in the upper range of past workplace exposures, or 20 ppm . Rat tumor response at lower concentrations below 20 ppm has not been adequately evaluated. However, based on analogy to more robust dose-response data from drinking water studies, it can be reasonably expected that airborne concentrations below 20 ppm would produce observable tumor response in rats.
The rat data predict signi cant CNS cancer risk to humans when current and historical workplace exposure levels are used, as shown in Table 1 . For example, at a 20-ppm exposure for 10 years, 19 excess CNS cancer deaths per 1,000 workers would be predicted. At 2 ppm, the current Occupational Safety and Health Administration standard in the U.S., the model predicts six excess brain cancer deaths after 30 years of exposure. These predictions are even more sobering because of recent comparative dosimetry work predicting that humans may experience higher brain concentrations of acrylonitrile's epoxide metabolite than do rats at the current occupational exposure standard of 2 ppm (Kedderis and Held, 1998) .
Epidemiology Studies
The epidemiology studies examine workers exposed to signi cant levels of acrylonitrile. Most workplace exposure to acrylonitrile results from inhalation, but exposure can also occur through the skin. Average inhalation exposure is generally highest in acrylic bers production, especially in the polymerization and spinning processes (IARC, 1979; Stewart et al., 1998) . Other signi cant exposures occur in the production of acrylonitrile, acrylonitrile-based resins, and nitrile rubber. Workers' exposures above 20 ppm time-weighted average for 8 h (TWA8) have occurred in the past, although current operations have exposures at or below 1 ppm TWA8 . Generally, exposure levels were higher in earlier years of operation . Only four of the studies provide exposure level estimates for acrylonitrile workers Collins et al., 1989; Swaen et al., 1998; Wood et al., 1998) . From these four studies, the average exposure level and duration appear consistent with 2 ppm for a 4-year duration as estimated by Ward and Starr (1993) . The exposure levels in these studies are probably characteristic of the other epidemiology studies because of the similarity of the operations across studies.
The epidemiology studies of acrylonitrile workers have examined incidence and death from cancers of the CNS. The classi cation of the CNS cancers in these studies presents several methodological problems. First, CNS cancers include all cancers of the brain, spinal cord, cranial nerves, and the meninges (International Classi cation of Disease, 1988) . Most of the CNS cancers (82%) are of the brain (Young et al., 1981) . Second, most of the epidemiology studies on acrylonitrile are mortality studies that use the underlying cause of death from a death certi cate to verify tumor diagnosis. Mortality studies often lack information on histology. We can assume most of the CNS cancers reported in these studies are glial neoplasms of the brain; 88% of adult brain primaries are astrocytomas (ICDO 940-944) (Velema and Percy, 1987) . Third, CNS tumors on death certi cates are classi ed as malignant , benign (ICD9 code 225), or unspeci ed as to malignancy (ICD9 code 237.5-237.9). If the attending physician records "brain tumor" on the certificate, the death will be coded as unspecified as to malignancy. Pathologic review of unspeci ed brain tumors indicated that most are primary malignant tumors (Thomas, 1994) . Deaths from benign and unspeci ed categories have not been reported in any of the studies of acrylonitrile workers. Fourth, not all brain tumors listed on the death certi cates are pathologically con rmed. Metastatic brain tumors are thus sometimes classi ed as primary brain tumors on the death certi cate. Between 1970 and 1971, 11% of the brain tumors identi ed on death certi cates were not primary brain tumors, according to hospital records . Between 1985 and , this percentage was reduced to 3% (Percy et al., 1990) . Finally, pathologic con rmation also may be more common among workers in industry, making it dif cult to chose an appropriate comparison group (Greenwald et al., 1981) . This nding has led to speculation that high brain cancer in some industrial cohorts could be attributed to a diagnostic bias from using the general population as a comparison group. With all these limitations, however, we conclude that most of the brain cancers that occur as an underlying Neuro-Oncology n JU LY 19 9 9 222 J.J. Collins and D.E. Strother: CNS tumors and acrylonitrile Based on Stewart et al. (1998) .
cause of death on the death certi cate are gliomas, and most of these gliomas are astrocytomas.
Methods
The epidemiology studies in this review were identi ed through a search of MEDLINE ® retrieval service for the period of 1970 to 1995. We searched for carcinogenicity and acrylonitrile and synonyms (cyanoethylene, 2-propenenitrile, vinyl cyanide, and acrylic ber). We also used reviews of acrylonitrile carcinogenicity (ATSDR, 1990; Doll, 1991; EPA, 1990; Guirguis et al., 1984; IARC, 1987; Koerselman and van der Graaf, 1984; Rothman 1994; Strother et al., 1988) to identify articles. We contacted companies making or using acrylonitrile and asked them for any unpublished studies on acrylonitrile. We also wrote to each author of the cohort studies for observed and expected deaths for brain cancer since they are not reported. Much of the data in this review have been presented previously (Collins and Acquavella, 1998) .
We identi ed 29 studies. Twenty-four were published, (Benn and Osborne, 1998; Blair et al., 1998; Chen et al., 1987 Chen et al., , 1988a Chen et al., , 1988b Collins et al., 1989; Delzell and Monson, 1982; Keisselbach et al., 1980; Marsh, 1983; Mastrangelo et al., 1993; O'Berg, 1980a O'Berg, , 1980b O'Berg et al., 1985; Ott et al., 1980 Ott et al., , 1989 Siemiatycki et al., 1994; Swaen et al., 1992 Swaen et al., , 1998 Thiess et al., 1980; Thomas et al., 1987; Waxweiler et al., 1981; Werner and Carter, 1981; Wood et al., 1998; Zhou and Wang, 1991) , and ve were unpublished ("The Mortality Experience of Monsanto Workers Exposed to Acrylonitrile" by Zack, "Cohort Mortality Study of Scotts Bluff/Baton Rouge Uniroyal Plant" by Herman, "A Mortality Study of Workers Potentially Exposed to Acrylonitrile During Start-up: Monsanto Decatur Plant" by Gaffey and Strauss, "Mortality and Cancer Incidence among Workers Exposed to Acrylonitrile at the Memphis Plant" by Burke, and "Mortality and Cancer Incidence among Workers Exposed to Acrylonitrile at the Beaumont Works" by Burke). We omitted two studies because they studied workers exposed to both dimethylformamide and acrylonitrile (Chen et al., 1988a (Chen et al., , 1988b , while a slightly earlier study on the same workforce provided data on only acrylonitrile workers (Chen et al., 1987) . We also omitted studies where the RR of CNS cancers was not reported or where we could not obtain this information from the authors. We included only the most recent study unless CNS cancers were not reported in the latest update (Benn and Osborne, 1998; Werner and Carter, 1981) . Twelve studies are included in the analysis to follow Chen et al., 1987; Delzell and Monson, 1982; Keisselbach et al., 1980; Mastrangelo et al., 1993; Swaen et al., 1998; Thiess et al., 1980; Thomas et al., 1987; Werner and Carter, 1981; Wood et al., 1998) , including unpublished studies of Herman and Burke (Memphis plant and Beaumont works).
To summarize the results of epidemiology studies, we used the methods of meta-analysis. Our analysis strategy focused on the evaluation of heterogeneity across studies as an indicator of factors that need to be considered in making a proper causal inference about acrylonitrile and CNS cancers. Precision issues were a subordinate concern. We evaluated heterogeneity via graphical and statistical methods as described by Greenland (1987) and Dickersin and Berlin (1992) . We used a xed effects model to calculate the mRR, a measure of the average ratio of disease rates for those with and without acrylonitrile exposure, as an inverse variance weighted average of RRs from the individual studies (Greenland, 1987) . We validated our calculations using Greenland's (1987) data for coffee and coronary heart disease and SAS software (SAS, 1993) . When signi cant heterogeneity occurred, we calculated mRRs and related CIs using a random effects model that includes an additional component to the variance of each study's RR to re ect greater than expected differences among studies. This additional variance component was computed from the heterogeneity chi-square statistic as described by Shadish and Haddock (1994) . The random effects model tends to equalize the contribution of individual studies to the mRR and increases the width of the CI.
The mRR calculations typically utilize a logarithmic transformation of CIs to derive standard errors and inverse variance weights. This transformation could not be utilized in studies where there were no exposed cases or where the lower confidence limit was 0. In these instances, we set the RR and lower con dence limit to 0.1, which will slightly increase the true mRR and slightly decrease the true heterogeneity estimates. We also evaluated these data excluding studies with a zero RR or lower con dence limit, and the results were similar.
We considered the impact on the mRR of a number of study characteristics including study design (cohort versus case-control), country (U.S. versus non-U.S.), and type of industry (acrylic fiber versus other). We also examined the impact of publication status and indicators of study quality. Personal or occupational confounding factors were not studied explicitly by any authors and, therefore, could not be considered in our analysis.
Publication bias is an important validity concern in meta-analysis; the publication process is selective. A related problem is that authors are selective in the reporting of ndings, especially for rare diseases such as CNS cancers. In situations where reporting was selective, we contacted authors to obtain missing data on CNS cancers and incorporated these data into our analyses. In some instances when expected CNS cancer deaths were not reported for a specific cancer, we estimated expected number of deaths or cases based on the ratio of expected numbers of CNS cancers to total cancer. We obtained the ratios of CNS cancers to total cancers from the largest studies (the Wood et al., 1998 , study for cancer incidence and the Blair et al., 1998 , study for cancer mortality).
The predominant focus in the available studies was on worker mortality rates. However, one employer's studies also evaluated cancer incidence data as determined from the company's insurance system. We consider the incidence data separately.
There is disagreement in the literature about whether study quality should be used to weigh results of metaanalyses. Arguments against this proposition are that there is no objective measure of study quality and that aspects of study quality may impart con icting effects on study results. Accordingly, Greenland proposed an analytic focus on individual aspects of study quality (Greenland, 1987) . We chose this approach as preferable to one that uses an overall quality score-weighting procedure. We used the percentage of vital status follow-up in the cohort studies as an indicator of study quality where studies of 95% or more were higher quality. We also used average duration of follow-up as another indicator of quality. Twenty or more years of average duration of follow-up was considered high quality. Finally, we considered studies with an exposure assessment to be of higher quality than studies which provided no exposure assessment.
We used an approach proposed by Ward and Starr (1993) to compare experimental animal ndings with epidemiology studies. We assumed that the average exposure in the epidemiology studies was 2 ppm, the average duration of exposure was 4 years, and the average length of follow-up was 20 years. Given the information from the three recent studies, these estimates are conservative Swaen et al., 1998; Wood et al., 1998) . The lifetime risk of developing CNS cancer from inhalation of acrylonitrile using the rat data is estimated to be 8.3 3 10 -5 per m g/m 3 by Ward and Starr (1993) . We detailed the Neuro-Oncology n JU LY 19 9 9 224 J.J. Collins and D.E. Strother: CNS tumors and acrylonitrile b Duration of follow-up was estimated from an earlier report (Delzell and Monson, 1981) .
c Incidence data were available but are not shown.
d More than half of the workers in the study were exposed in ber operations.
P-value function for the RR estimates to depict precision of the estimates unencumbered by speci cation of a condence level (Poole, 1987) . We used methods described by Breslow and Day (1987) to examine mortality trends for individual studies by exposure levels. Table 2 provides details of the studies that were used in the analysis. There is one case-control study and 11 cohort studies. This case-control study used ICD9 codes of 191, 192, 225, and 239.7 for possible cases, and then matched these possible cases with hospital records. Only astrocytoma, glioblastoma multiforme, and mixed glioma with astrocytic cells were included as cases. The 11 cohort studies only examined malignant CNS cancers, although six of these studies did not report how they de ned CNS cancers (unpublished Burke Memphis plant and Beaumont works; Delzell and Monson, 1982; Mastrangelo et al., 1993; Swaen et al., 1998; Thiess et al., 1980) , and one study only reports on malignant brain cancer (Werner and Carter, 1981) . The predominant industries in the cohort studies were monomer production and ber and resin manufacture. Overall, there were 60 deaths from cancers of the CNS, 27 in the case-control study and 33 in the cohort studies. There were also ve incident cases from the studies of Burke (unpublished Beaumont works and unpublished Memphis plant) and Wood et al. (1998) not shown in the table. The average length of follow-up in the cohort studies ranged from 10 to 28 years, and the percentage of vital status follow-up ranged from 88 to 100%. Fig. 1 presents the RRs and CIs for the 12 studies included in the analysis. The studies of Keisselbach et al. (1980) , Werner and Carter (1981) , Herman (unpublished), Burke (unpublished, Memphis plant), Mastrangelo et al. (1993) , and Swaen et al. (1998) report RRs for brain or CNS cancers in excess of 1.0. The studies of Delzell and Monson (1982) and Burke (unpublished, Beaumont plant) report no CNS cancer deaths. The three recent cohort studies of Swaen et al. (1998) , Wood et al. (1998) , and Blair et al. (1998) are very large, as indicated by their narrow con dence limits, and have RR very close to 1.0.
Results
Only three studies reported rates of CNS cancers by level or duration of exposure. These studies are shown in Table 3 with the rat ndings of Quast et al. 3 The rates of CNS cancers in the rat study show increasing risk of astrocytoma with increasing exposure level. The RR is 6.0 (95% CI 3.1-10.5) at 20 ppm lifetime exposure and 21.6 (95% CI 15.6-29.1) at 80 ppm lifetime exposure. The three epidemiology studies of Thomas et al. (1987) , Swaen et al. (1998), and Blair et al. (1998) show no increasing risk with increasing exposure.
The mRRs and CIs for several groupings of data are presented in Table 4 . The three studies that examined CNS cancer incidence had a mRR of 1.1 (95% CI 0.4-3.6), and the ndings were consistent across studies as indicated by the P value for heterogeneity (0.61). This mRR was based on just ve cases. The data from the 12 mortality studies included in the analysis produce a mRR of 1.1 (95% CI 0.8-1.5), and the ndings were consistent (P value = 0.20). Since the mRRs for incidence and mortality are similar, we focused the remainder of the analysis and discussion on the mortality data.
The studies done on U.S. workers (mRR = 0.9, 95% CI 0.6-1.3) have a lower mRR than studies done on non-U.S. workers (mRR = 2.2, 95% CI 1.2-4.3). There was no difference in the mRR for acrylic ber operations (mRR = 1.1, 95% CI 0.6-1.8) versus non ber operations (mRR = 1.1, 95% CI 0.8-1.7). Although the estimates were imprecise, the RRs were higher in the unpublished studies (mRR = 2.3, 95% CI 0.6-9.3) than in the published studies (mRR = 1.1, 95% CI 0.7-1.2). There also was a tendency not to report RRs >1.0. Studies reporting expected deaths had a mRR of 1.0 (95% CI 0.7-1.4) compared with a mRR of 2.2 (95% CI 0.3-2.2) for studies not reporting expected deaths. The studies with vital status follow-up completion of 95% or greater had lower mRR (1.1, 95% CI 0.7-16) than studies with follow-up completion <95% (mRR = 2.5, 95% CI 0.8-7.6). The studies with average duration of follow-up >20 years had a mRR of 0.9 (95% CI 0.6-1.5) compared with a mRR of 2.8 among studies with <20 years average duration of follow-up. Studies with an exposure assessment had a mRR of 1.0 (95% CI 0.6-1.5) compared with studies with no exposure assessment that had a mRR of 2.5 (95% CI 1.2-5.4). Fig. 2 presents the projected deaths from CNS cancers using the animal data and human data modeled according to Ward and Starr (1993) assuming an average exposure of 2 ppm for 4 years with 20 years of follow-up. The model predicts a RR of 2.4 (95% CI 2.0-2.8) from the animal data compared with a RR of 1.0 (95% CI 0.7-1.3) in the epidemiology data. The P-value functions in Fig. 2 indicate that the CIs for the animal and human data do not overlap. We also used the other exposure assumption of Ward and Starr (1993) . At an average exposure of 5 ppm for 4 years of exposure with 20 years of follow-up, the RR was 4.5 (95% CI 3.9-5.0). If we want to make the human and the animal ndings consistent, we could assume an average exposure in the epidemiology studies of 0.005 ppm for 4 years after 20 years of follow-up.
Discussion
Most of the epidemiology studies that examine CNS cancer rates among acrylonitrile workers are cohort mortality investigations. The cohort studies in this review range in size from 327 to 25,460. These studies include 37,352 workers and 33 CNS cancer deaths. The single case-control study reported 27 astrocytoma deaths among workers with potential acrylonitrile exposure.
The general diagnosis of CNS cancers in the cohort studies precluded our examining CNS cancers by cell type or location in the CNS. However, because most CNS cancer deaths in humans are in the brain and most brain cancers are astrocytomas, the cohort studies would be able to detect a moderate increase of astrocytomas deaths among acrylonitrile workers.
The levels of acrylonitrile exposure in all the studies are uncertain. Personal monitoring for acrylonitrile was not available before the mid-1970s, making exposure estimation before this time dif cult. This lack of information made it impossible for us to examine exposure response for all studies or focus analysis on the highest exposed workers who would be most appropriate for an evaluation of acrylonitrile carcinogenicity. Some of the large recent cohort studies did estimate exposures in the past, and thus were more useful for causal inference. These large studies did not nd an exposure response.
Evaluation of exposure to acrylonitrile in the case study of Thomas et al., however, was based on job history by next of kin. Jobs considered to have potential exposure to acrylonitrile in this study were primarily farmers. Acrylonitrile is a registered pesticide in the U.S. Acrylonitrile rarely has been used as a pesticide in the U.S., however, and its use is restricted to certi ed applicators (IARC, 1979) . Therefore, it is unlikely that any farmers included in the Thomas et al. study had signicant exposures to acrylonitrile.
Given the limitations just mentioned, the mRRs for CNS cancers are near null and consistent with no effect from acrylonitrile exposure. There was a tendency not to report positive ndings for CNS cancers. For example, the three unpublished studies had a mRR of 2.3 (95% CI 0.6-9.3) compared with a mRR of 1.1 (95% CI 0.8-1.5) for nine published studies. This is directly opposite of what we expected if publication bias were present. Studies Neuro-Oncology n JU LY 19 9 9 226 J.J. Collins and D.E. Strother: CNS tumors and acrylonitrile <0.13, 0.13-0.57, 0.57-1.5, 1.5-8.0, >8.0) with increased RRs tend to be more often reported than studies with null ndings . Because CNS cancers were not the major focus of any of the cohort studies, the high rates of CNS cancers in the unpublished studies could result from chance. The CNS ndings in the unpublished studies are based on only six CNS cases. The higher quality cohort studies had a lower risk of CNS cancers than did the lower quality studies. Studies with average duration of follow-up of >20 years had a mRR of 0.9 (95% CI 0.6-1.5) compared with a mRR of 2.8 (95% CI 1.3-6.0) for the studies with <20 years of follow-up. The same pattern is observed when we examine the quality measure of vital status follow-up completion. The non-U.S. studies also had a higher mRR than the U.S. studies. This most likely re ects the fact that some of the non-U.S. studies had shorter follow-up periods and had lower percentages of vital status follow-up. We also observed that studies with an exposure assessment had a mRR of 1.0 (95% CI 0.6-1.5), while studies with no exposure assessment had a mRR of 2.5 (95% CI 1.2-5.4). The higher quality studies indicate no increased CNS cancer risk. However, while publication and study quality biases may be present in these studies, they do not have signi cant impact on the overall size of mRR since the largest studies are both published and of high quality.
The experimental studies on rats show an association between acrylonitrile exposure and brain tumors. However, there was no indication in the epidemiology data of increased cancer risk among acrylonitrile workers. The animal and the human ndings are inconsistent. There are several explanations that could explain the discrepancy.
The relevance of the acrylonitrile-induced rat CNS tumors to humans is not well understood. The histogenesis of the rat tumors, for example, has not been de nitively established (Bigner et al., 1986) . They are clearly primary brain tumors and have similarities to the spontaneous tumors that arise in rats, but they differ from the nitrosourea-induced tumors and virus-induced tumors that have the hallmarks of astrocytic lineage in rats. Also, the mechanism(s) that give rise to acrylonitrile-induced rat brain tumors are not well understood. Acrylonitrileinduced CNS tumors have not been linked to DNA adducts (Whysner et al., 1998a) . Research investigating alternative mechanisms to direct genotoxicity has recently been reported (Jiang and Klaunig, 1998; Whysner et al., 1998b) . This work shows elevated levels of oxidative DNA damage in the brains of rats exposed to tumorigenic doses of acrylonitrile, as indicated by the presence of 8-oxodeoxyguanosine, and considers the possibility that acrylonitrile may selectively induce oxidative stress in rat brain. Existing evidence suggests a need to better understand the rat as a CNS tumor model for predicting human response to acrylonitrile. Acrylonitrile, while causing CNS tumors in rats, may not cause CNS tumors in humans. Because rats have been generally exposed to higher levels of acrylonitrile than have humans, the doseresponse curve may be nonlinear at low doses. However, given the relatively narrow margin between past and current workplace standards and airborne concentrations that are tumorigenic in the rat, it seems unlikely that the striking differences between rat and human response to acrylonitrile exposure can be explained solely on the basis of faulty dose extrapolation. This is further reinforced if one considers the results of dosimetry modeling suggesting that humans may experience equivalent or higher tissue concentrations of acrylonitrile and its epoxide metabolite than do rats at current workplace exposure standards of 2 ppm (Kedderis and Held, 1998) .
Only 33 CNS cancers have been reported among the acrylonitrile workers in the 11 cohort studies that have been done. These cancers are rare in humans, and the heterogeneity of CNS cancers will make the identi cation of causes dif cult when they are grouped together as in the present case (Davis et al., 1996) . While we can be somewhat certain that acrylonitrile exposure does not cause a large increase in risk in brain tumors, especially in astrocytomas as a group, we cannot be certain that a small increased risk is not present, especially among the rarer histologic types.
To compare the rat ndings with the human ndings, we had to translate the animal exposure to an exposure observed in the workplace. Increased risk of CNS cancer in rats is observed after a lifetime exposure to 20 ppm. A small percentage of workers in the epidemiology studies have been exposed to 20 ppm TWA8 or more but these workers would only be exposed to these levels for a few years. So the animals received a higher cumulative exposure to acrylonitrile than humans. It could be that humans are exposed to less acrylonitrile than we have estimated, thus explaining the differences in risk by adjusting for dose.
Limitations in the design and execution of the epidemiology studies may have obscured a CNS cancer excess among exposed workers. We have already discussed the inability of the case-control study design to identify workers with signi cant exposure to acrylonitrile. Another potential limitation of the epidemiology studies is the short duration of follow-up of workers after exposure. Several epidemiology studies have only examined mortality rates of workers for <20 years after rst exposure. If acrylonitrile exposure only leads to cancer deaths >20 years after exposure, these studies could not assess acrylonitrile carcinogenicity. Fortunately, the three recent large studies of acrylonitrile workers overcome these two limitations and can thus validly assess acrylonitrile carcinogenicity.
Conclusion
High exposure to acrylonitrile in rats increases their cancer risk. However, there is no indication of increased risk in humans exposed to lower levels of acrylonitrile. It is apparent that the animal risk from acrylonitrile exposure is not consistent with the extensive epidemiology data on acrylonitrile workers. While there are several possible explanations for this inconsistency, it may be that the ndings in animals are not relevant to humans. Because of the rarity of CNS cancer in humans, however, and the lack of causal mechanisms of these tumors in rats, a more definitive conclusion will have to await additional experimental and observational data. Nevertheless, the epidemiology data indicate that acrylonitrile is not a potent CNS tumorigen in humans.
Neuro-Oncology n JU LY 19 9 9 228 J.J. Collins and D.E. Strother: CNS tumors and acrylonitrile Fig. 2 . P-value function of the projected relative risk for brain cancers from animal data and the actual relative risk from human studies.
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